Expertise in
2
conditions

Dr. Michael E. Luggen

Rheumatology
University Of Cincinnati Physicians Company LLC
3188 Bellevue Ave, 
Cincinnati, OH 
 (823.4 mi)
Accepting New Patients
Expertise in
2
conditions
University Of Cincinnati Physicians Company LLC
3188 Bellevue Ave, 
Cincinnati, OH 
 (823.4 mi)
OverviewInsuranceLocationsClinical Research

Overview

Michael Luggen is a Rheumatologist in Cincinnati, Ohio. Dr. Luggen is highly rated in 2 conditions, according to our data. His top areas of expertise are Rheumatoid Arthritis (RA), Arthritis, Polymyalgia Rheumatica, and Rhizomelic Pseudopolyarthritis. Dr. Luggen is currently accepting new patients.

His clinical research consists of co-authoring 11 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Rheumatology
Licenses
Internal Medicine in OH
Hospital Affiliations
University Of Cincinnati Medical Center, LLC
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Medical Health
  •  CareSource
  •  Humana

Locations

UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY LLC
3188 Bellevue Ave, Cincinnati, OH 45219

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
Enrollment Status: Active_not_recruiting
Publish Date: January 22, 2025
Intervention Type: Drug
Study Drugs: Baricitinib, TNF Inhibitor
Study Phase: Phase 4
A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study Comparing GSK3196165 With Placebo and With Tofacitinib, in Combination With Methotrexate in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study Comparing GSK3196165 With Placebo and With Tofacitinib, in Combination With Methotrexate in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
Enrollment Status: Completed
Publish Date: March 27, 2024
Intervention Type: Biological, Drug
Study Drugs: GSK3196165, Tofacitinib, Methotrexate, Folic acid
Study Phase: Phase 3
A Multi-centre Long-term Extension Study to Assess the Safety and Efficacy of GSK3196165 in the Treatment of Rheumatoid Arthritis
A Multi-centre Long-term Extension Study to Assess the Safety and Efficacy of GSK3196165 in the Treatment of Rheumatoid Arthritis
Enrollment Status: Terminated
Publish Date: February 07, 2024
Intervention Type: Drug, Biological
Study Drugs: Otilimab, csDMARD
Study Phase: Phase 3
A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: October 12, 2023
Intervention Type: Drug
Study Drugs: Olokizumab, Methotrexate
Study Phase: Phase 3
A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Tumor Necrosis Factor Alpha (TNF-α) Inhibitor Therapy
A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Tumor Necrosis Factor Alpha (TNF-α) Inhibitor Therapy
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Drug
Study Drug: Olokizumab
Study Phase: Phase 3
A 24-week, Phase 3, Multicentre, Randomised, Double-blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Sarilumab, in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological DMARDs and/or Janus Kinase Inhibitors
A 24-week, Phase 3, Multicentre, Randomised, Double-blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Sarilumab, in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological DMARDs and/or Janus Kinase Inhibitors
Enrollment Status: Completed
Publish Date: July 17, 2023
Intervention Type: Drug, Biological
Study Drugs: GSK3196165, Sarilumab, csDMARDs
Study Phase: Phase 3
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Enrollment Status: Terminated
Publish Date: May 16, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
Enrollment Status: Terminated
Publish Date: January 30, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
Enrollment Status: Completed
Publish Date: November 23, 2022
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
View 8 Less Clinical Trials

11 Total Publications

Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment.
Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment.
Journal: Annals of the rheumatic diseases
Published: December 29, 2023
Similar Doctors
Expertise in
25
conditions
Dr. Gregory J. Delorenzo
Rheumatology
Expertise in
25
conditions
Dr. Gregory J. Delorenzo
Rheumatology

Trihealth H LLC

379 Dixmyth Ave, 
Cincinnati, OH 
 (1.0 mi)
513-246-7000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Gregory Delorenzo is a Rheumatologist in Cincinnati, Ohio. Dr. Delorenzo is highly rated in 25 conditions, according to our data. His top areas of expertise are Rheumatoid Arthritis (RA), Psoriatic Arthritis, Gout, and Psoriasis. Dr. Delorenzo is currently accepting new patients.

Expertise in
8
conditions
Dr. Hermine I. Brunner
Pediatric Rheumatology | Rheumatology
Expertise in
8
conditions
Dr. Hermine I. Brunner
Pediatric Rheumatology | Rheumatology
3333 Burnet Ave, Mlc 4010, 
Cincinnati, OH 
 (1.1 mi)
513-636-4676
Languages Spoken:
English, German, Portuguese
See accepted insurances
Accepting New Patients

Hermine Brunner is a Pediatric Rheumatologist and a Rheumatologist in Cincinnati, Ohio. Dr. Brunner is highly rated in 8 conditions, according to our data. Her top areas of expertise are Juvenile Idiopathic Arthritis (JIA), Systemic Lupus Erythematosus (SLE), Lupus Nephritis, and Arthritis. Dr. Brunner is currently accepting new patients.

Expertise in
9
conditions
Dr. Louis E. Flaspohler
Rheumatology
Expertise in
9
conditions
Dr. Louis E. Flaspohler
Rheumatology
2355 Norwood Ave, Suite 1, 
Cincinnati, OH 
 (4.3 mi)
513-351-0800
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Louis Flaspohler is a Rheumatologist in Cincinnati, Ohio. Dr. Flaspohler is highly rated in 9 conditions, according to our data. His top areas of expertise are Undifferentiated Connective Tissue Disease (UCTD), IgG4-Related Disease, MAGIC Syndrome, and Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcus Infections. Dr. Flaspohler is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile